Market capitalization | $63.72m |
Enterprise Value | $57.04m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 570.40 |
P/S ratio (TTM) P/S ratio | 637.20 |
P/B ratio (TTM) P/B ratio | 9.79 |
Revenue growth (TTM) Revenue growth | 607.14% |
Revenue (TTM) Revenue | $100.00k |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
1 Analyst has issued a forecast Entera Bio Ltd.:
1 Analyst has issued a forecast Entera Bio Ltd.:
Sep '24 |
+/-
%
|
||
Revenue | 0.10 0.10 |
900%
900%
|
|
Gross Profit | -0.02 -0.02 |
60%
60%
|
|
EBITDA | -9.17 -9.17 |
8%
8%
|
EBIT (Operating Income) EBIT | -9.22 -9.22 |
8%
8%
|
Net Profit | -9.18 -9.18 |
8%
8%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Entera Bio Ltd. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of orally delivered large molecule therapeutics. It develops an oral formulation of parathyroid hormone. The company was founded on June 1, 2010 and is headquartered in Jerusalem, Israel.
Head office | Israel |
CEO | Miranda Toledano |
Employees | 37 |
Founded | 2009 |
Website | www.enterabio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.